A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Description

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Conditions

Metastatic Colorectal Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Condition
Metastatic Colorectal Cancer
Intervention / Treatment

-

Contacts and Locations

Scottsdale

Research Site, Scottsdale, Arizona, United States, 85259

Los Angeles

Research Site, Los Angeles, California, United States, 90089

Washington

Research Site, Washington, District of Columbia, United States, 20007

Chicago

Research Site, Chicago, Illinois, United States, 60637

Baltimore

Research Site, Baltimore, Maryland, United States, 21224

Boston

Research Site, Boston, Massachusetts, United States, 02114

Rochester

Research Site, Rochester, Minnesota, United States, 55905

Rochester

Research Site, Rochester, New York, United States, 14618

Cleveland

Research Site, Cleveland, Ohio, United States, 44106

Houston

Research Site, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histopathologically confirmed colorectal adenocarcinoma.
  • * Provision of FFPE tumor sample collected as per SoC.
  • * Presence of measurable disease by RECIST 1.1 criteria.
  • * ECOG performance status of 0 or 1.
  • * Life expectancy ≥ 12 weeks at the time of screening.
  • * Central nervous system metastases or spinal cord compression
  • * Known history of severe allergy to any monoclonal antibody or study intervention.
  • * Any unresolved toxicity CTCAE Grade ≥ 2 from a previous anticancer therapy.
  • * History of another primary malignancy.

Ages Eligible for Study

18 Years to 130 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

AstraZeneca,

Study Record Dates

2028-01-12